Back to School: How biopharma can reboot drug development. Access exclusive analysis here

BBR 3576: Phase II

NOV said that in an open-label Phase II trial, 15 of 61 evaluable patients with hormone resistant prostate cancer (HRPC) who

Read the full 218 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE